AnaptysBio, Inc. ANAB Biopharma Company — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s biopharma company — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s biopharma company — operating income?
- AnaptysBio, Inc. (ANAB) reported biopharma company — operating income of -$52.81M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — operating income changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — operating income decreased by 3.0% year-over-year, from -$51.28M to -$52.81M.
- What does biopharma company — operating income mean?
- This metric measures the profitability of the company's core operations by subtracting total operating expenses from revenue. For clinical-stage biopharma companies, this is typically negative, reflecting significant investment in pipeline development before commercialization. It serves as a key indicator of the company's operational financial health and the extent of its reliance on external financing.